The first meeting of IMMUPARKNET COST Action 21117 took place last February in Istanbul, Turkey. The meeting gathered several researchers, clinicians, and students from our network to foster fruitful discussions about immunity’s role in Parkinson’s disease.
Share this post
A new study published in “The Lancet Neurology” investigates whether azathioprine, a common immunosuppressant, could represent a breakthrough in slowing the progression of Parkinson’s Disease...
We are pleased to announce that the fourth and final Annual Conference of the IMMUPARKNET Action will take place in Coimbra, Portugal, from 12 to...
We are pleased to announce that the call for grant applications for Grant Period 4 of ImmuParkNet is now open. This call covers activities to...
COST Action IMMUPARKNET is pleased to present its Gender Equality Plan (GEP) 2025, a strategic document that reflects on the progress made and sets out...
We are pleased to invite you to the upcoming IMMUPARKNET Training School on Immune Profiling in Parkinson’s Disease: Designing Observational Clinical Studies Venue: Instituto de...
On the past 17-19 October 2025, members of IMMUPARKNET COST Action met at the The Cyprus Institute of Neurology and Genetics, Nicosia, Cyprus, to discuss...